OptiNose Inc (OPTN)
OPTN
ENT
BiotechSign Signal Grade
F
Signal Grade
16.7/100 composite signal score
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Insider Buying
0
Publications
100
Clinical Activity
25
Pipeline Overview
- Therapeutic Focus
- ENTsrc
Clinical Trial Activity
1
Clinical Trial
(ClinicalTrials.gov aggregate)
(ClinicalTrials.gov aggregate)
1 Phase 3
Trial Phase Breakdown
5
PubMed Publications
0
Catalyst Records
ClinicalTrials.gov aggregate as of 2026-10-16. ClinicalTrials.gov
Recent News & SEC Filings
- SEC 8-K 8-K - Current report
- SEC 8-K 8-K - Current report
- SEC 8-K 8-K - Current report
- SEC 8-K 8-K - Current report
- SEC 8-K 8-K - Current report
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Systemic Corticosteroids in the Management of Sinonasal Disease: An Evidence-Based Expert Review. — Int Forum Allergy Rhinol 2026 Aug PMID 42411021
- Comparative Efficacy of Recombinant C1 Inhibitor Versus Sebetralstat for On-Demand Treatment of Hereditary Angioedema Attacks: A Matching-Adjusted Indirect Treatment Comparison. — Adv Ther 2026 Jul PMID 42068479
- Coexisting Type 2 Inflammatory Conditions in Patients with Asthma Treated with Dupilumab: the RAPID Registry. — Adv Ther 2026 Jul PMID 42060163
- The pro-doc-tivity pause: Health economic benefits of collegial connection. — Ann Allergy Asthma Immunol 2026 Jul PMID 41999987
- Understanding Biologics in CRSwNP: Related Events and Insights. — Curr Allergy Asthma Rep 2026 Mar 30 PMID 41910874
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for OptiNose Inc.
Full OPTN Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.